[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334613-105":59,"doc-detail-334613-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-targeting-at-genome-mutations-of-liver-cancer-by-the-insertion-of-hsv1-thymidine-kinase-through-cas9-mediated-editing","Therapeutic targeting at genome mutations of liver cancer by the insertion of HSV1 thymidine kinase through Cas9-mediated editing","","Liver cancer remains among the most lethal human malignancies, and treatment options for advanced-stage disease are limited. This study developed a Cas9-mediated genome-editing approach to insert a suicide gene, herpes simplex virus type 1 thymidine kinase, at mutation sites in liver cancer. The strategy was tested across three mutations, achieving high insertion rates and demonstrating reduced tumor burden and improved survival in both mouse spontaneous and xenografted liver cancer models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-targeting-at-genome-mutations-of-liver-cancer-by-the-insertion-of-hsv1-thymidine-kinase-through-cas9-mediated-editing/334613/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-targeting-at-genome-mutations-of-liver-cancer-by-the-insertion-of-hsv1-thymidine-kinase-through-cas9-mediated-editing/334613.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment strategy did the study develop for liver cancer?","Question",{"text":112,"@type":113},"The study developed a Cas9-mediated genome-editing strategy to insert HSV1 thymidine kinase as a suicide gene at specific liver cancer mutation sites, combined with prodrug use.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which mutations were targeted and how were insertion efficiencies reported?",{"text":117,"@type":113},"Three mutation scenarios were targeted: S45P in catenin beta 1, a chromosome breakpoint in an SLC45A2-AMACR fusion, and V235G in SAFB-like transcription modulator. Insertion efficiencies were reported at 77.8% for S45P, 95.1%–98.7% for the fusion breakpoint, and 51.4% for V235G.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were observed in mouse models after treatment?",{"text":121,"@type":113},"In mice with spontaneous liver cancer and in xenografted models, the targeting reagent reduced tumor burden and metastasis and improved survival compared with control-treated groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334613,1790019574,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","DOI: 10.1097/HC9.0000000000000412  \nO R IG INAL ART ICL E  \nTherapeutic targeting at genome mutations of liver cancer by the insertion of HSV1 thymidine kinase through Cas9-mediated editing  \nMuhamuda Kader1 | Wei Sun 1 | Bao-Guo Ren 1 | Yan-Ping Yu1,2 | Junyan Tao 1 | Lesley M. Foley3 | Silvia Liu1,2 | Satdarshan P. Monga 1,2 | Jian-Hua Luo1,2   \n1Department of Pathology, University of Pittsburg School of Medicine, Pittsburgh, Pennsylvania, USA  \n2Pittsburgh Liver Research Center at Pittsburgh Liver Institute, Animal Imaging Center, University of Pittsburg School of Medicine, Pittsburgh, Pennsylvania, USA 3University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA  \nCorrespondence  \nJian-Hua Luo, Department of Pathology, University of Pittsburgh School of Medicine, 3550 Terrace Street, Scaife S-728, Pittsburgh, PA 15261, USA.  \nEmail: [luoj@upmc.edu](luoj@upmc.edu)  \n\n|  | Abstract |  |\n| --- | --- | --- |\n| | Background: Liver cancer is one of the most lethal malignancies for humans. The treatment options for advanced-stage liver cancer remain limited. A new treatment is urgently needed to reduce the mortality of the disease. Methods: In this report, we developed a technology for mutation site insertion of a suicide gene (herpes simplex virus type 1- thymidine kinase) based on type II CRISPR RNA-guided endonuclease Cas9-mediated genome editing to treat liver cancers.\u003Cbr>Results: We applied the strategy to 3 different mutations: S45P mutation of catenin beta 1, chromosome breakpoint of solute carrier family 45 member 2-alpha-methylacyl-CoA racemase gene fusion, and V235G mutation of SAFBlike transcription modulator. The results showed that the herpes simplex virus type 1-thymidine kinase insertion rate at the S45P mutation site of catenin beta 1 reached 77.8%, while the insertion rates at the breakpoint of solute carrier family 45 member 2 – alpha-methylacyl-CoA racemase gene fusion were 95. 1%–98 .7%, and the insertion at V235G of SAFB-like transcription modulator was 51 .4% . When these targeting reagents were applied to treat mouse spontaneous liver cancer induced by catenin beta 1S45P or solute carrier family 45 member 2-alpha-methylacyl-CoA racemase, the mice experienced reduced tumor burden and increased survival rate. Similar results were also obtained for the xenografted liver cancer model: Significant reduction of tumor volume, reduction of metastasis rate, and improved survival were found in mice treated with the targeting reagent, in comparison with the control-treated groups. |  |\n|  |  |  |\n\nAbbreviations: AMACR, alpha-methylacyl-CoA racemase; Cas9, type II CRISPR RNA-guided endonuclease Cas9; CTNNB1, catenin beta 1; EGFP, enhanced green fluorescent protein; HMET, MET proto-oncogene, receptor tyrosine kinase; SCID, severe combined immuno-deficiency; SLAM, SLC45A2-AMACR; SLTM, SAFB-like transcription modulator; SLC45A2, solute carrier family 45 member 2; SNV, single nucleotide variants; tk, thymidine kinase.  \nThe authors Muhamuda Kader, Wei Sun, and Bao-Guo Ren contributed equally.  \n-- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -  \nThis is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nCopyright © 2024 The Author(s) . Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.  \n|  | Conclusions: Our studies suggested that mutation targeting may hold promise as a versatile and effective approach to treating liver cancers. |  |\n| --- | --- | --- |\n|  |  |  |\n\nINTRODUCTION  \nLiver cancer is one of the most lethal malignancies for humans. In 2022, 29,380 people in the United States died from liver cancer.[1] Worldwide, mortality for liver cancer reached 830,180 in 2019 .[2] HCC has been the dominant liv","cbCaivdRH1kC9ujx","https://ap.wps.com/l/cbCaivdRH1kC9ujx","pdf",1098295,13,"English","# Background\n# Methods\n## Cell lines\n# Results\n# Conclusions","[{\"question\":\"What treatment strategy did the study develop for liver cancer?\",\"answer\":\"The study developed a Cas9-mediated genome-editing strategy to insert HSV1 thymidine kinase as a suicide gene at specific liver cancer mutation sites, combined with prodrug use.\"},{\"question\":\"Which mutations were targeted and how were insertion efficiencies reported?\",\"answer\":\"Three mutation scenarios were targeted: S45P in catenin beta 1, a chromosome breakpoint in an SLC45A2-AMACR fusion, and V235G in SAFB-like transcription modulator. Insertion efficiencies were reported at 77.8% for S45P, 95.1%–98.7% for the fusion breakpoint, and 51.4% for V235G.\"},{\"question\":\"What outcomes were observed in mouse models after treatment?\",\"answer\":\"In mice with spontaneous liver cancer and in xenografted models, the targeting reagent reduced tumor burden and metastasis and improved survival compared with control-treated groups.\"}]","Therapeutic targeting at genome mutations of liver cancer by the insertion of HSV1 thymidine kinase through Cas9-mediated editing | PDF",1790007469,33]